• Ramón Lecumberri, Isabel Krsnik, Elham Askari, Maialen Sirvent, Marta S González-Pérez, Fernando Escalante, Virginia Pradillo, Luis E Tamariz, Verónica Cánovas, Adrián Alegre, Mercedes Gironella, María E González-García, María S Infante, Sunil Lakhwani, Cristina Martínez-Bilbao, Victoria Dourdil, Ángel Ramírez-Payer, José Sarrá, and M Teresa Cibeira.
• Hematology Department, Clínica Universidad de Navarra, Pamplona, Spain.
• Amyloid. 2020 Sep 1; 27 (3): 163-167.

AbstractManagement of patients with relapsed or refractory (R/R) AL amyloidosis is complex. Some initial reports have shown positive results with daratumumab in heavily pre-treated AL amyloidosis patients. In this retrospective multicentric study, 38 patients (mean age 64 ± 9 years) with R/R AL amyloidosis treated with daratumumab were included. Cardiac and renal involvement was present in 76 and 74% of patients, and 42% had ≥3 organs involved. Median number of previous lines of therapy was 2 (range 1-8). Overall hematological response was 72%, including 28% complete responses. The median time to first hematological response was 2 weeks. A high-quality response (≥very good partial response) was obtained in 65% of patients who had never achieved such depth of response previously. Hematological responses were more frequent among patients receiving daratumumab as second-line therapy compared to subsequent therapies (92 vs. 61%). Cardiac and renal organ response rates were 37 and 59%. At 12 months, overall and progression-free survival were 59% (95%CI: 0.36-0.77) and 52% (95%CI: 0.29-0.70), respectively. Daratumumab is a safe and effective drug in the treatment of R/R AL amyloidosis and should be considered early in the course of the disease.

23 keywords...

hide…